PMID: 6170472Jan 1, 1981Paper

Combined chemotherapy of head and neck squamous cell carcinomas with methotrexate, bleomycin, and hydroxyurea

Cancer Chemotherapy and Pharmacology
R MedenicaW Lehmann

Abstract

Thirty-two patients with squamous cell carcinoma of head and neck not amenable to surgery or radiotherapy were treated with a combination of methotrexate 0.6 mg/kg IV weekly, bleomycin 15 mg IV weekly, and hydroxyurea 1,000 mg/m2 three oral doses weekly. Eleven complete responses and ten partial responses of more than 50% were observed. The mean duration was 43 weeks for complete responses and 35 weeks for partial responses. Toxicity consisted in leukopenia, thrombocytopenia, nausea, vomiting, stomatitis, and cutaneous alterations. Only one patient suffered reversible lung toxicity. These results suggest that a combination of three drugs in squamous cell head and neck cancer may be more effective than a combination of bleomycin and methotrexate only.

References

Jul 5, 1975·British Medical Journal·L A PriceK B Hughes

❮ Previous
Next ❯

Citations

Sep 1, 1994·European Journal of Cancer. Part B, Oral Oncology·W Dörr, M Hönig
Sep 1, 1996·European Journal of Cancer. Part B, Oral Oncology·K J KairemoS Bondestam
Jul 11, 1998·Oral Oncology·W ParulekarR C Jordan
Jan 1, 1985·Seminars in Surgical Oncology·P B DesaiV S Swaroop

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
W DörrM Hönig
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
L VanuytselE van der Schueren
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
K Sakamoto
© 2021 Meta ULC. All rights reserved